CoChat

Canagliflozin extends life span in genetically heterogeneous male but not female mice

Open access
Miller, Richard A., Harrison, David E., Allison, David B., Bogue, Molly, Debarba, Lucas, Diaz, Vivian, Fernandez, Elizabeth, Galecki, Andrzej, Garvey, W. Timothy, Jayarathne, Hashan, Kumar, Navasuja, Javors, Martin A., Ladiges, Warren C., Macchiarini, Francesca, Nelson, James, Reifsnyder, Peter, Rosenthal, Nadia A., Sadagurski, Marianna, Salmon, Adam B., Smith, Daniel L., Snyder, Jessica M., Lombard, David B., Strong, Randy · 2020 · JCI Insight
Cited by 125

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Canagliflozin (Cana) is an FDA-approved diabetes drug that protects against cardiovascular and kidney diseases. It also inhibits the sodium glucose transporter 2 by blocking renal reuptake and intestinal absorption of glucose. In the context of the mouse Interventions Testing Program, genetically heterogeneous mice were given chow containing Cana at 180 ppm at 7 months of age until their death. Cana extended median survival of male mice by 14%. Cana also increased by 9% the age for 90th percentile survival, with parallel effects seen at each of 3 test sites. Neither the distribution of inferred cause of death nor incidental pathology findings at end-of-life necropsies were altered by Cana. Moreover, although no life span benefits were seen in female mice, Cana led to lower fasting glucose and improved glucose tolerance in both sexes, diminishing fat mass in females only. Therefore, the life span benefit of Cana is likely to reflect blunting of peak glucose levels, because similar longevity effects are seen in male mice given acarbose, a diabetes drug that blocks glucose surges through a distinct mechanism, i.e., slowing breakdown of carbohydrate in the intestine. Interventions that control daily peak glucose levels deserve attention as possible preventive medicines to protect from a wide range of late-life neoplastic and degenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.140019

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 125

Metadata

Authors
Miller, R. A., Harrison, D. E., Allison, D. B., Bogue, M., Debarba, L., Diaz, V., Fernandez, E., Galecki, A., Garvey, W. T., Jayarathne, H., Kumar, N., Javors, M. A., Ladiges, W. C., Macchiarini, F., Nelson, J., Reifsnyder, P., Rosenthal, N. A., Sadagurski, M., Salmon, A. B., Smith, D. L., Snyder, J. M., Lombard, D. B., & Strong, R.
Venue
JCI Insight
Published
2020-11-05
Volume
5
Issue
21
ISSN
2379-3708 (ISSN-L)
OpenAlex
W3091049124
Cited by
125
References
12
FWCI
3.77
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Canagliflozin extends life span in genetically heterogeneous male but not female mice. https://app.cochat.ai/papers/10.1172/jci.insight.140019
The paper
Miller, R. A., Harrison, D. E., Allison, D. B., Bogue, M., Debarba, L., Diaz, V., Fernandez, E., Galecki, A., Garvey, W. T., Jayarathne, H., Kumar, N., Javors, M. A., Ladiges, W. C., Macchiarini, F., Nelson, J., Reifsnyder, P., Rosenthal, N. A., Sadagurski, M., Salmon, A. B., . . . Strong, R. (2020). Canagliflozin extends life span in genetically heterogeneous male but not female mice. JCI Insight. https://doi.org/10.1172/jci.insight.140019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.